Reimbursement is the milestone Teal Health is now chasing. The San Francisco company raised $22 million in a Series A, and its self-collection kit for HPV testing has already won regulatory authorization in the United States. Executives expect payer coverage to widen in January 2027.
.406 Ventures led the round. Emerson Collective, Forerunner and Serena Ventures returned, and Japan’s MPower Partners joined as a new investor, lifting total funding to $45 million.
The product is the Teal Wand, a self-collection device that lets a patient gather a sample without a speculum or an in-office appointment. Collection is paired with a telehealth consultation, secure delivery of results and access to follow-up care when needed.
The gap it targets is stubborn. Teal cites figures showing nearly one in three U.S. women is behind on cervical cancer screening. Appointment scarcity, clinician shortages, scheduling friction and an uncomfortable exam all push women away.
Self-collection is not a new idea, but regulatory and reimbursement pathways have lagged the underlying science. FDA authorization plus a stated coverage date moves the format out of pilot projects and into a billing conversation, which is usually the line between a demonstration and a service.
Open questions remain. A mailed device shifts responsibility for sample quality onto the patient, and follow-up rates after an abnormal result will decide whether at-home screening narrows disparities or quietly widens them.
